Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The main objective of the study is to see if using anti-inflammatory to patients with airway
disease chronic obstructive pulmonary disease (COPD) phenotype will be more effective than
using these treatments in patients with loss of lung tissue. Symbicort plus
ipratropium/albuterol will be used for 12 weeks in an open-label study in subjects with
airway predominant COPD.
Phase:
Phase 4
Details
Lead Sponsor:
National Jewish Health
Collaborator:
AstraZeneca
Treatments:
Albuterol Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate Ipratropium